

Granulomatous Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/G3653DE10081EN.html>

Date: May 2024

Pages: 132

Price: US\$ 6,499.00 (Single User License)

ID: G3653DE10081EN

Abstracts

The 7 major granulomatous disease markets are expected to exhibit a CAGR of 4.6% during 2024-2034.

The granulomatous disease market has been comprehensively analyzed in IMARC's new report titled "Granulomatous Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Granulomatous disease refers to a group of medical conditions characterized by the formation of granulomas, which are clusters of immune cells that assemble in response to chronic inflammation. These conditions result from the body's attempt to contain substances that it perceives as foreign or harmful but is unable to eliminate. Granulomas are composed of lymphocytes, macrophages, and other immune cells that surround the offending agent. The symptoms of this ailment can vary widely, depending on the condition and the organs affected. Common indications include fatigue, fever, weight loss, and localized discomfort or pain. The organ systems commonly affected are the lungs, skin, liver, and lymph nodes. Diagnosing granulomatous disease involves a combination of clinical evaluation, medical history assessment, imaging studies (such as X-rays, CT scans, or MRIs), and often a biopsy of the affected tissue. Laboratory tests to evaluate inflammatory markers and immune responses also contribute to the diagnostic process.

The increasing cases of infections, particularly those caused by intracellular pathogens that evade the immune system, are primarily driving the granulomatous disease market. In addition to this, the inflating utilization of effective therapeutic agents, including corticosteroids, immunosuppressants, and biologic drugs, for managing symptoms and curbing the progression of the ailment is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive measures, such as pulmonary

rehabilitation and nutritional counseling, which aid in enhancing lung function and overall well-being, is further bolstering the market growth. Apart from this, the rising usage of targeted procedures like laser therapy that selectively alleviate granulomas and promote tissue healing in individuals suffering from the ailment is acting as another significant growth-inducing factor. Additionally, the emerging popularity of supportive therapies, including physiotherapy and respiratory therapy, since they are aimed at mitigating disease complications, such as lung fibrosis, is also augmenting the market growth. These interventions are critical for improving the quality of life for patients by enhancing respiratory function and serving as adjuncts to conventional medical treatments. Furthermore, the escalating advancements in diagnostic procedures, like flow cytometry tests that detect the absence or malfunction of essential proteins in white blood cells, are expected to drive the granulomatous disease market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the granulomatous disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for granulomatous disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the granulomatous disease market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the granulomatous disease market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the granulomatous disease market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current granulomatous disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report

Market Insights

How has the granulomatous disease market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the granulomatous disease market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the granulomatous disease market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of granulomatous disease across the seven major markets?

What is the number of prevalent cases (2018-2034) of granulomatous disease by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of granulomatous disease by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with granulomatous disease across the seven major markets?

What is the size of the granulomatous disease patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of granulomatous disease?

What will be the growth rate of patients across the seven major markets?

Granulomatous Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for granulomatous disease drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the granulomatous disease market?

What are the key regulatory events related to the granulomatous disease market?

What is the structure of clinical trial landscape by status related to the granulomatous disease market?

What is the structure of clinical trial landscape by phase related to the granulomatous disease market?

What is the structure of clinical trial landscape by route of administration related to the granulomatous disease market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 GRANULOMATOUS DISEASE - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
- 4.4 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
- 4.5 Competitive Intelligence

5 GRANULOMATOUS DISEASE - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 GRANULOMATOUS DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (?2018-2023?)
 - 7.2.2 Epidemiology Forecast (?2024-2034?)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (?2018-2023?)
 - 7.3.2 Epidemiology Forecast (?2024-2034?)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (?2018-2023?)
 - 7.4.2 Epidemiology Forecast (?2024-2034?)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (?2018-2023?)
 - 7.5.2 Epidemiology Forecast (?2024-2034?)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (?2018-2023?)
 - 7.6.2 Epidemiology Forecast (?2024-2034?)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (?2018-2023?)
 - 7.7.2 Epidemiology Forecast (?2024-2034?)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (?2018-2023?)
 - 7.8.2 Epidemiology Forecast (?2024-2034?)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (?2018-2023?)
 - 7.9.2 Epidemiology Forecast (?2024-2034?)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 GRANULOMATOUS DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 GRANULOMATOUS DISEASE - UNMET NEEDS

10 GRANULOMATOUS DISEASE - KEY ENDPOINTS OF TREATMENT

11 GRANULOMATOUS DISEASE - MARKETED PRODUCTS

- 11.1 List of Granulomatous Disease Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Actimmune (Interferon gamma-1b) - Horizon Therapeutics plc
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 GRANULOMATOUS DISEASE - PIPELINE DRUGS

12.1 List of Granulomatous Disease Pipeline Drugs Across the Top 7 Markets

12.1.1 Drug Name – Company Name

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. GRANULOMATOUS DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. GRANULOMATOUS DISEASE – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 GRANULOMATOUS DISEASE - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Granulomatous Disease - Market Size

15.2.1.1 Market Size (?2018-2023?)

15.2.1.2 Market Forecast (?2024-2034?)

15.2.2 Granulomatous Disease - Market Size by Therapies

15.2.2.1 Market Size by Therapies (?2018-2023?)

15.2.2.2 Market Forecast by Therapies (?2024-2034?)

15.3 Market Scenario - United States

15.3.1 Granulomatous Disease - Market Size

15.3.1.1 Market Size (?2018-2023?)

15.3.1.2 Market Forecast (?2024-2034?)

15.3.2 Granulomatous Disease - Market Size by Therapies

15.3.2.1 Market Size by Therapies (?2018-2023?)

15.3.2.2 Market Forecast by Therapies (?2024-2034?)

- 15.3.3 Granulomatous Disease - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Granulomatous Disease - Market Size
 - 15.4.1.1 Market Size (?2018-2023?)
 - 15.4.1.2 Market Forecast (?2024-2034?)
 - 15.4.2 Granulomatous Disease - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (?2018-2023?)
 - 15.4.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.4.3 Granulomatous Disease - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Granulomatous Disease - Market Size
 - 15.5.1.1 Market Size (?2018-2023?)
 - 15.5.1.2 Market Forecast (?2024-2034?)
 - 15.5.2 Granulomatous Disease - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (?2018-2023?)
 - 15.5.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.5.3 Granulomatous Disease - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Granulomatous Disease - Market Size
 - 15.6.1.1 Market Size (?2018-2023?)
 - 15.6.1.2 Market Forecast (?2024-2034?)
 - 15.6.2 Granulomatous Disease - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (?2018-2023?)
 - 15.6.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.6.3 Granulomatous Disease - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Granulomatous Disease - Market Size
 - 15.7.1.1 Market Size (?2018-2023?)
 - 15.7.1.2 Market Forecast (?2024-2034?)
 - 15.7.2 Granulomatous Disease - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (?2018-2023?)
 - 15.7.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.7.3 Granulomatous Disease - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Granulomatous Disease - Market Size
 - 15.8.1.1 Market Size (?2018-2023?)
 - 15.8.1.2 Market Forecast (?2024-2034?)
 - 15.8.2 Granulomatous Disease - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (?2018-2023?)

- 15.8.2.2 Market Forecast by Therapies (?2024-2034?)
- 15.8.3 Granulomatous Disease - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Granulomatous Disease - Market Size
 - 15.9.1.1 Market Size (?2018-2023?)
 - 15.9.1.2 Market Forecast (?2024-2034?)
 - 15.9.2 Granulomatous Disease - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (?2018-2023?)
 - 15.9.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.9.3 Granulomatous Disease - Access and Reimbursement Overview

16 GRANULOMATOUS DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 GRANULOMATOUS DISEASE MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 GRANULOMATOUS DISEASE MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Granulomatous Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/G3653DE10081EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3653DE10081EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

